A peptide made by your mitochondria (your cells' energy factories) that helps regulate metabolism and energy.
Metabolic health, insulin sensitivity, and exercise performance.
Discovered only in 2015 — there are essentially no human treatment trials yet. True frontier territory.
What it is
MOTS-c was discovered only in 2015, which makes it the newest compound in this guide by a significant margin. What makes it scientifically unusual is where it comes from: most peptides are encoded by the DNA in your cell nuclei, but MOTS-c is encoded by mitochondrial DNA — the separate genetic material inside your mitochondria, your cells' energy-producing structures. It functions as a kind of metabolic status signal. When your body is under metabolic stress — during exercise, caloric restriction, or aging — MOTS-c levels rise. It activates AMPK, a master regulator of cellular energy that plays a key role in how your body processes glucose, builds or burns fat, and responds to physical activity. Observational data shows that MOTS-c levels decline with age, and that people who live to 100 tend to have higher levels. What that means for taking it externally as a supplement hasn't been established in human clinical trials. This is genuinely frontier territory.
Potential benefits
Metabolic Health & Insulin Sensitivity
Mouse studies: improved insulin sensitivity, reduced obesity, reversed diet-induced metabolic dysfunction. Observational human data shows lower MOTS-c in obesity, T2DM, and metabolic syndrome. Interventional human data essentially absent.
Exercise Performance & Muscle Function
Levels rise with exercise in humans. Animal studies show enhanced physical performance and reduced fatigue. Whether exogenous administration replicates these effects in exercising humans is not established.
Aging & Longevity
Declines with age. Higher levels in centenarians (observational). Aged mouse studies show improved function after administration. Correlative — not causal human evidence.
Anti-Inflammatory / Bone Health
Animal and cell culture data suggest anti-inflammatory effects and protective effects on bone density. Early-stage.
Risks and contraindications
Side Effects
- Injection site reactions
- Fatigue or energy fluctuation — anecdotal
- Nausea · Myalgias — reported
- No serious adverse events formally reported — reflects scarcity of research, not established safety
Theoretical Risks
- AMPK chronic exogenous activation — systemic metabolic consequences unknown
- Mitochondrial feedback loop disruption
- AMPK has complex cancer biology — net effect in cancer-risk populations unknown
- Interaction with metformin (also AMPK activator) — additive pathway effects
Contraindications / cautions
- Active cancer · Pregnancy · Breastfeeding · Under 18
- Metformin, insulin, or diabetes medications (caution — AMPK overlap)
- Mitochondrial disease · Active inflammatory conditions
Research reality
Promising and mechanistically credible. Mouse studies have shown improved insulin sensitivity, better metabolic function, and exercise enhancement — findings that are consistent with what we know about AMPK biology. Genuinely interesting preclinical data.
Essentially absent for anyone actually taking it as a treatment. The human data that exists is observational — measuring naturally occurring MOTS-c levels in different populations. No completed randomized trials of giving MOTS-c to people have been published.
Doesn't exist. MOTS-c was identified in 2015. This is the newest compound in the guide, and using it clinically means operating without any human safety data at all — true research frontier territory.
Novel, scientifically credible concept — mitochondrial-derived peptides are a genuine research frontier. The biology is compelling. The human evidence is nearly nonexistent. Anyone considering this should understand clearly that they'd be among the earliest people to use it in a clinical context — true frontier territory.